Tracers / [68Ga]Ga-PSMA-11
[68Ga]Ga-PSMA-11
Also written as [68Ga]Ga-PSMA-11; [68Ga]Ga-PSMA-HBED-CC; [68Ga]Ga-PSMA11; [68Ga]PSMA-11; [68Ga]PSMA-HBED-CC; [Ga-68]Ga-PSMA-11; [Ga-68]Ga-PSMA-HBED-CC
- Radionuclide
- Ga-68 t½ 67.7 min
- Modality
- PET
- Production route
- Generator / Cyclotron liquid target
- Stage
- Approved
- Syntheses indexed
- 108
What it is
- Compound class
- Small molecule (urea-based)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA / glutamate carboxypeptidase II) PMID 28283702 / DOI 10.1007/s00259-017-3670-z
- Clinical application
- Prostate cancer staging and biochemical recurrence PMID 28283702 / DOI 10.1007/s00259-017-3670-z
- Theranostic pair
- <a href="/tracers/lu177-psma617/">lu177-psma617</a>
Regulatory status
- FDA
- Yes — 2020; gallium Ga 68 gozetotide (NDA 212642 UCLA / NDA 212643 UCSF); commercial kits Illuccix (Telix, 2021), Locametz (Novartis, 2022), Gozellix (Telix, 2025) Drugs@FDA, NDA 212642 & 212643, approved 2020-12-01 (kits NDA 214032 / 215841 / 219592) — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=gozetotide
- EMA (centralised)
- Yes — 2022; Locametz (gozetotide); Novartis Europharm Limited; EMEA/H/C/005488 EMA medicines register, EPAR Locametz, marketing authorisation issued 2022-12-09 — https://www.ema.europa.eu/en/medicines/human/EPAR/locametz
- Other approvals
- —
- Brand names
- Illuccix; Locametz; Gozellix (US, FDA); Locametz (EU, EMA)
Clinical use
- Typical injected activity
- ~150-200 MBq (e.g. 182 +/- 47 MBq); ~1.8-2.2 MBq/kg per EANM/SNMMI guideline PMID 38761312 / DOI 10.1007/s12149-024-01939-z; PMID 28283702 / DOI 10.1007/s00259-017-3670-z
- Uptake time
- 50-100 min post-injection (typically ~60 min) PMID 28283702 / DOI 10.1007/s00259-017-3670-z
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Advion NanoTek Advion | custom manifold | — | — | — | PSMA-HBED-CC ABX | 27090254 2016 EJNMMI Res using an Advion NanoTek LF system containing a flow-through microreactor |
| GAIA V2 Elysia-Raytest | vendor cassette | none | 89.55 ± 5.49 | >99% | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem Generators elution was performed using the GAIA® V2 module (Elysia-Raytest, Germany) controlled via the dedicated software (GAIA Control, Elysia-Raytest, Germany). — after process optimization, routine RCY improved to 89.55 ± 5.49% |
| Manual synthesis | fixed tubing | none | 88.41 ± 4.72 | 99.59% ± 0.35% by TLC and 98.75% ± 0.31% by HPLC | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem 68Ga eluates were used without elution processing, after elution of either one or two GalliAd® generators. — RCY (%) (mean value) 76.80 ± 5.4488.41 ± 4.72 |
| GAIA V2 Elysia-Raytest | vendor cassette | none | 70.46 ± 2.64 | 99.93 ± 0.06% by HPLC and 99.74 ± 0.27% by iTLC | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem Two GalliaPharm® generators were eluted using an automated fractionation method. 1.7 mL of 0.1 M HCl from the more recently installed generator and 0.7 mL from the older generator were collected, for a total of 2.4 mL per aliquot. — The RCY for the three validation batches was 70.46 ± 2.64%, and 66.31 ± 6.78% in routine production |
| Manual synthesis | fixed tubing | none | 78.79 ± 4.60 | 95.84% ± 4.94% by TLC and 93.72% ± 4.39% by HPLC | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem Two GalliAd® generators were manually eluted in sequence (1.1 mL of 0.1 M HCl each) and combined directly in the aliquot vial. — RCY (%) (mean value) 70.46 ± 2.6478.79 ± 4.60 |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | none | 91-102% yes | 98.0-99.6% | Locametz® kit (gozetotide, PSMA-11) Novartis | 38632189 2024 EJNMMI Radiopharm Chem a Scintomics® GRP 3V module (Scintomics® GmbH, Fürstenfeldbruck, Germany) — Radiolabelling with one and two generator(s) resulted in a radiochemical yield of 91–102% and 96–101% after preparation, respectively. |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | none | 96-101% yes | 98.4-99.3% | Locametz® kit (gozetotide, PSMA-11) Novartis | 38632189 2024 EJNMMI Radiopharm Chem a Scintomics® GRP 3V module (Scintomics® GmbH, Fürstenfeldbruck, Germany) — Radiolabelling with one and two generator(s) resulted in a radiochemical yield of 91–102% and 96–101% after preparation, respectively. |
| GAIA Elysia-Raytest | vendor cassette | SPE | 68.3% ± 2.1% | 97.72% ± 0.04% (TLC); 91.24% to 94.81% (HPLC) | PSMA-11 ABX | 38424422 2024 Curr Radiopharm A GAIA® synthesis module and a GALLIAD® generator were used. — These three validation batches were produced with a mean RCY of 68.3% ± 2.1%. |
| In-house / custom built | custom manifold | SPE | 83 ± 11% yes | >99% | PSMA-11 precursor ABX | 39407503 2024 Molecules Synthesis of [68Ga]Ga-PSMA-11 using concentrated Ga-68 was conducted on a Teflon-coated silicon chip patterned with a circle hydrophilic reaction site, operated on a temperature-controlled heating platform — the final product was obtained with a high radiochemical yield (RCY) of 83 ± 11% (n = 3) |
| miniAllinOne Trasis | vendor cassette | SPE | 45.8 ± 29.4 | 71.8% | PSMA-11 Iason GmbH | 38004410 2023 Pharmaceuticals (Basel) radiosynthesis was performed on MiniAIO® synthesis module (Trasis®, Ans, Belgium) — The mean labeling yields for double elution with prepurification were 45.8 ± 29.4 (mean ± standard deviation) |
| miniAllinOne Trasis | vendor cassette | SPE | 97.5 ± 1.9 | — | PSMA-11 Iason GmbH | 38004410 2023 Pharmaceuticals (Basel) radiosynthesis was performed on MiniAIO® synthesis module (Trasis®, Ans, Belgium) — The mean labeling yields for the fractionated double elution were 97.5 ± 1.9 (mean ± standard deviation) |
| GAIA V2 Elysia-Raytest | vendor cassette | SPE | 81 ± 3% no | >95% | PSMA-11 Advanced Biochemical Compounds, ABX, Germany | 35337140 2022 Pharmaceuticals (Basel) Synthesis was performed on a fully automated radiosynthesis cassette module (GAIA V2™, Elysia-Raytest, Straubenhard, Germany) — a high (81 ± 3% non-decay corrected) and highly reproducible RCY |
| iQS-TS | — | SPE | 86.82% ± 2.57% | more than 99% | PSMA-11 | 35177423 2022 J Nucl Med An iQS-TS automated module was used for all radiolabeling steps — yield rates of 88.07% ± 1.26% and 86.82% ± 2.57%, respectively |
| Modular-Lab PharmTracer Eckert & Ziegler | vendor cassette | SPE | >85% no | 99.06 ± 0.10% | Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11) ABX | 33918987 2021 Pharmaceuticals (Basel) an automated Modular-Lab PharmTracer synthesis module (Eckert and Ziegler—Berlin, Germany) for routine production — Radiolabeling yields of >85% were obtained. |
| iPHASE MultiSyn iPHASE Technologies | vendor cassette | SPE | 76 ± 3 yes | 99.9 ± 0.2 | PSMA-11 ABX | 33067810 2021 J Labelled Comp Radiopharm iPHASE MultiSyn module — Formulated and sterile radiopharmaceuticals were obtained in 76 ± 3% (n = 20) and 91 ± 4% (n = 15) radiochemical yields after 17 and 20 min, respectively. |
| GAIA V2 Elysia-Raytest | vendor cassette | — | 91% vs 43% no | — | PSMA-11 Advanced Biochemical Compounds, ABX, Germany | 33761040 2021 EJNMMI Radiopharm Chem loaded in an automated radiosynthesis module (GAIA V2™, Elysia-Raytest, Germany), by using disposable reagents assembled in a disposable sterile cassette. — a decrease in the percentage of radiolabeling yield non-decay corrected (n.d.c.) at end of synthesis (EOS) (i.e., 91% vs 43%) |
| — | — | — | — | — | — | 34529005 2021 JAMA Oncol |
| FASTlab Developer GE HealthCare | vendor cassette | SPE | — yes | 99.4 | PSMA-11 precursor | 33180205 2020 EJNMMI Radiopharm Chem GE FASTlab Developer platform |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | PSMA-11 ABX | 32939194 2020 World J Nucl Med the Scintomics GRP module was used for automated synthesis |
| Scintomics GRP / GRP-3V Scintomics | — | SPE | — | — | PSMA-11 ABX | 32410136 2020 EJNMMI Radiopharm Chem The syntheses were performed using a GRP® synthesis module from Scintomics (Fürstenfeldbruck, Germany) with the cationic concentration protocol provided by Scintomics. |
| ITG labeling module ITG (Isotope Technologies Garching) | — | SPE | more than 95% | 99.6 ± 0.1% | HBED-CC-Lys-CO-Glu (Glu-urea-Lys(Ahx)-HBED-CC) | 29853810 2018 Contrast Media Mol Imaging 68Ga-PSMA-11 was semiautomatically synthesized using the labeling module (iTG) as shown in Supplemental Figure 1. — The radiochemical yield of 68Ga-PSMA-11 from the synthesis module was more than 95%. |
| — | — | — | — | — | — | 40638023 2025 Ann Nucl Med |
| — | — | — | — | — | — | 31855410 2020 Bioconjug Chem |
| — | — | — | — | — | — | 40580320 2025 Eur J Nucl Med Mol Imaging |
| iQS-TS ITG (Isotope Technologies Garching) | vendor cassette | SPE | 63.4 | 99.3 | PSMA-11 | 34658552 2021 Indian J Nucl Med Hot cell to house 68Ga iQS-TS Synthesis module, ITG, Germany — 68Ga PSMA-11 13 63.4±2.2 4-6 99.3±0.2 |
| — | — | — | — | — | PSMA-HBED-CC | 38424612 2024 Cancer Imaging |
| GAIA V2 Elysia-Raytest | vendor cassette | none | 89.55 ± 5.49% | > 99% | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem Generators elution was performed using the GAIA® V2 module (Elysia-Raytest, Germany) — after process optimization, routine RCY improved to 89.55 ± 5.49% |
| Kit-based preparation | vendor cassette | none | 80.07 ± 1.71% | 99.99% ± 0.01% | PSMA-11 Novartis | 42251618 2026 EJNMMI Radiopharm Chem lyophilized PSMA-11 kits (Locametz®, Novartis, France) were reconstituted with 1 mL of water for injection — RCY (%) (mean value) 83.53 ± 6.16 80.07 ± 1.71 |
| — | — | — | — | — | — | 41886137 2026 Curr Treat Options Oncol |
| Scintomics GRP / GRP-3V | vendor cassette | SPE | 62 | >99% for 68Ga-PSMA | PSMA-HBED-CC | 41824275 2026 EJNMMI Radiopharm Chem an automated synthesis module (Scintomics GRP®, Fürstenfeldbruck, Germany) — assuming a reference radiolabelling yield of 62% |
| — | — | — | — | — | — | 41771032 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41489652 2026 Eur J Nucl Med Mol Imaging |
| Modular-Lab Standard Eckert & Ziegler | — | — | 94.31±6.18 | >95% | PSMA-11 | 41370506 2025 Einstein (Sao Paulo) the standardization of the automated synthesis process using a Modular-Lab Standard module (Eckert & Ziegler) — Labeling Yield (%)89.03±3.7894.31±6.18 |
| Manual synthesis | — | none | — | >97% | PSMA-11 trifluoroacetate salt (precursor A) / PSMA-11/Mannitol (precursor B) ABX | 40941986 2025 Molecules PSMA-11 precursor and 5 mg of ascorbic acid dissolved in 1 mL of acetate buffer were added to a vial containing about 5 mL of gallium-68 chloride in 0.1 M hydrochloric acid. The vial was placed in a heating block preheated to 95 °C and incubated for 5 min. — The labeling of [68Ga]Ga-PSMA-11 was performed using activities that yielded final product activities in the range of 1090–3095 MBq, with most values exceeding 2000 MBq. |
| Kit-based preparation POLATOM | vendor cassette | none | — | >97% | PSMA-11 kit for radiolabeling POLATOM | 40941986 2025 Molecules The labeling procedure of the precursor C was performed according to the standard kit manufacturer’s instruction. — The labeling of [68Ga]Ga-PSMA-11 was performed using activities that yielded final product activities in the range of 1090–3095 MBq, with most values exceeding 2000 MBq. |
| — | — | — | — | — | — | 40638023 2025 Ann Nucl Med |
| — | — | — | — | — | — | 40448740 2025 Curr Urol Rep |
| — | — | — | — | — | — | 40414994 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 40304782 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 40213671 2025 Theranostics |
| Manual synthesis | — | — | — | more than 95% | PSMA-11 ABX | 40147849 2025 J Nucl Med 68Ga radiolabeling of PSMA-11 was done by eluting a 68Ge/68Ga generator (ITM Medical Isotopes GmbH) with 4 mL of 0.05 M hydrochloric acid into a 1-mL sodium acetate buffer containing 35 µg of PSMA-11. |
| Kit-based preparation | — | HPLC | >97% | — | PSMA-11 ABX | 40135799 2025 J Med Chem PSMA-11 (4–8 μg ≙ 4.2–8.4 nmol; ABX advanced biochemical compounds GmbH, Radeberg, Germany) was labeled with 68GaCl3 (150 to 250 MBq) in 400 μL ammonium acetate (2 M) and HCl at pH 4.5. — The radiochemical yield for [68Ga]Ga-PSMA-11 was >97% |
| — | — | — | — | — | — | 39878896 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39794510 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39743616 2025 Eur J Nucl Med Mol Imaging |
| Kit-based preparation Novartis | vendor cassette | — | 95.03% no | 98.41 ± 0.47% | PSMA-11 Novartis | 39692998 2024 EJNMMI Radiopharm Chem Cold kit labeling is expected to facilitate global access to 68Ga-labeled radiopharmaceuticals including [68Ga]Ga-PSMA-11 — Using the Locametz kits, the overall production success rate was 95.03% (172/181). |
| Kit-based preparation Telix Pharmaceuticals | vendor cassette | — | 99.22% no | 97.81 ± 0.71% | PSMA-11 Telix Pharmaceuticals | 39692998 2024 EJNMMI Radiopharm Chem Cold kit labeling is expected to facilitate global access to 68Ga-labeled radiopharmaceuticals including [68Ga]Ga-PSMA-11 — Using Illuccix kits (n = 256), the overall production success rate was 99.22% (254/256). |
| — | — | — | — | — | PSMA-11 (Glu-CO-Lys-Ahx-HBED-CC) | 39661209 2024 EJNMMI Radiopharm Chem |
| FASTlab 2 GE HealthCare | custom manifold | none | — | 98.83 ± 0.19 | HBED-CC-PSMA-11 ABX | 39598846 2024 Molecules Automated labeling of the precursor was accomplished using a FASTLab 2 synthesizer. |
| In-house / custom built | custom manifold | SPE | 83 ± 11% yes | >99% | PSMA-11 precursor ABX | 39407503 2024 Molecules microdroplet synthesis of [68Ga]Ga-PSMA-11 — the final product was obtained with a high radiochemical yield (RCY) of 83 ± 11% (n = 3) |
| — | — | — | — | — | — | 39268679 2024 Cancer Biother Radiopharm |
| — | — | — | — | — | — | 39207485 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39136560 2024 Radiology |
| — | — | — | — | — | — | 39060832 2024 Ann Nucl Med |
| — | — | — | — | — | — | 38948055 2024 Theranostics |
| — | — | — | 98% | 99% | HBED-CC | 38855174 2024 Theranostics |
| — | — | — | — | — | — | 38760451 2024 Sci Rep |
| — | — | — | — | — | — | 38724653 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | HBED-CC | 38577331 2024 Front Oncol |
| — | — | — | — | — | PSMA-HBED-CC | 38424612 2024 Cancer Imaging |
| GAIA Elysia-Raytest | vendor cassette | SPE | 68.3% ± 2.1% | 97.72% ± 0.04% | PSMA-11 ABX | 38424422 2024 Curr Radiopharm A GAIA® synthesis module and a GALLIAD® generator were used. — These three validation batches were produced with a mean RCY of 68.3% ± 2.1%. |
| — | — | — | — | — | PSMA-11 ABX | 37889298 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 36302657 2023 J Nucl Med |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | PSMA ABX | 35889351 2022 Molecules the automated synthesis module Scintomics GRPTM (Scintomics GmbH, Fürstenfeldbruck, Germany) |
| miniAllinOne Trasis | vendor cassette | none | 80.98 ± 0.05% (L); 71.48 ± 0.04% (H) no | 99.91% (L); 99.96% (H) | PSMA-11 ABX | 35744985 2022 Molecules Radiosyntheses were performed using an All In One mini automated synthesizer (Trasis, Ans, Belgium) and cassettes without pre-purification after generator elution. — The average value of RCY for L activity, not corrected for decay, was 80.98 ± 0.05%, decreasing to 71.48 ± 0.04% for H activity. |
| — | — | — | — | — | — | 35406542 2022 Cancers (Basel) |
| — | — | — | — | >97% | PSMA-11 | 35056066 2021 Pharmaceuticals (Basel) |
| Manual synthesis | — | — | — | — | PSMA-11 ABX | 34370181 2022 Mol Imaging Biol [68Ga]Ga-PSMA-11 and [18F]F-JK-PSMA-7 were labeled according to standard protocols, which have been published elsewhere [18]. |
| — | — | — | — | — | PSMA-11 | 33778927 2021 Curr Oncol Rep |
| — | — | — | — | — | — | 33674398 2021 J Nucl Med |
| — | — | — | — | — | — | 33465252 2021 Prostate |
| — | — | — | — | — | — | 31940969 2020 Pharmaceuticals (Basel) |
| Manual synthesis | — | — | — | — | — | 31107537 2019 Mutagenesis [68Ga]Ga-PSMA-11 was radiosynthesised as previously described (13). |
| Advion NanoTek Advion | custom manifold | — | — | — | PSMA-HBED-CC ABX | 27090254 2016 EJNMMI Res Ga-68-radiolabeling of PSMA-HBED-CC (ABX, GMP grade) was performed using an Advion NanoTek LF system containing a flow-through microreactor |
| — | — | — | 2841 ± 584 MBq yes | >99% | — | 42496850 2026 Ann Nucl Med synthesized using an automated module — a decay-corrected radiochemical yield of 2841 ± 584 MBq |
| — | — | — | — | — | — | 40132471 2025 Eur J Radiol |
| — | — | — | 1.52 GBq | >95 % | [68Ga]GaCl3 | 38447298 2024 Nucl Med Biol used to label 1 NetSpot and 2 Illuccix kits simultaneously — [68Ga]GaCl3 was added to 2.5 mL of buffer which gave 1.52 GBq of [68Ga]Ga-PSMA-11 |
| — | — | — | — | — | gallium (68 Ga) chloride | 35869898 2022 J Labelled Comp Radiopharm The first method for the [68 Ga]Ga-PSMA11 radiopharmaceutical was performed with the automated synthesis module, which is widely used in clinical practice. |
| — | — | — | — | — | gallium (68 Ga) chloride | 35869898 2022 J Labelled Comp Radiopharm Radiolabeling success, suitability of quality control parameters, and in vitro stability of [68 Ga]Ga-PSMA11 radiopharmaceutical performed with ANMI kit were examined. |
| — | — | — | — | — | gallium (68 Ga) chloride | 35869898 2022 J Labelled Comp Radiopharm Direct cold labeling of PSMA11 ligand with sodium bicarbonate buffer was examined. |
| — | — | — | 51.2% | — | 68Zn | 34763197 2022 Nucl Med Biol using a single FASTlab time-list — a radiochemical yield of 51.2% was produced in 63 min |
| — | — | — | — | >99% | 68Zn | 34763197 2022 Nucl Med Biol by kit labeling (N = 1) |
| — | — | — | — | — | PSMA-11 | 32865290 2020 J Labelled Comp Radiopharm Cold-kits or automated synthesis are viable options for standardized methods |
| — | — | — | — | — | PSMA-11 | 32865290 2020 J Labelled Comp Radiopharm a manual kit-based method with a module-based automated synthesis approach |
| — | — | — | — | — | PSMA-HBED-CC | 32374450 2020 J Labelled Comp Radiopharm using the Trasis miniAllinOne radiosynthesizer |
| — | — | — | — | — | — | 31601704 2020 J Nucl Med synthesized using ... synthesis modules |
| — | — | — | — | — | — | 31601704 2020 J Nucl Med a sterile cold kit was recently introduced |
| — | — | SPE | — | >99% | PSMA-11 | 32796487 2020 Nucl Med Commun The radiosynthesis of [Ga]Ga PSMA-11 was performed using a Trasis MiniAio synthesizer |
| — | — | — | 70% | >99% | — | 32632739 2020 Mol Imaging Biol a microfluidic chip was assembled in polydimethylsiloxane (PDMS), combining all components of tracer production in an integrated, compact, and easily utilized platform — with an average radiochemical yield of 70 % |
| — | — | — | 84.2 ± 6.3% | >95% | PSMA-HBED-CC | 32796488 2020 Nucl Med Commun previously used Modular-Lab module — Automated module-involved synthesis of [Ga]Ga-PSMA-HBED- CC resulted in a radiochemical yield of 84.2 ± 6.3% |
| — | — | — | >98% | >95% | PSMA-HBED-CC | 32796488 2020 Nucl Med Commun For labeling with the lyophilized cold kit isoPROtrace-11, 2.5 ml 0.1 M HCl of the middle Ga-68 elution fraction were added to the kit — The room temperature cold kit gave a radiochemical yield of >98% |
| — | — | — | 77% ± 2% | exceeding 97% | PSMA-11 | 30672007 2019 J Labelled Comp Radiopharm Automated production of [68 Ga]Ga-DOTANOC and [68 Ga]Ga-PSMA-11 using a TRACERlab FXFN synthesis module. — Activity yields were 77% ± 2% for [68 Ga]Ga-PSMA-11 |
| — | — | — | 84 ± 6% | >98% | — | 28950199 2017 Appl Radiat Isot |
| — | — | — | — | >95% | — | 27907840 2017 Nucl Med Biol without use of any synthesis module |
| — | — | SPE | 93.19%±3.76% | >99% | PSMA-11 ligand | 27231953 2016 Nucl Med Biol using (68)Ge/(68)Ga generator and a manual synthesis module, both supplied by Isotope Technologies Garching (ITG), Germany — The radiochemical yields obtained were consistently high, 93.19%±3.76% |
| — | — | SPE | 49 ± 1.2 % yes | ≥98 % | PSMA-HBED (Glu-NH-CO-NH-Lys(Ahx)-HBED-CC) | 25869080 2015 Mol Imaging Biol |
| — | — | — | — | — | — | 41006727 2025 Med Oncol |
| — | — | — | — | — | PSMA-11 | 31845408 2020 J Labelled Comp Radiopharm utilizing a cassette module (GAIA; Elysia-Raytest; Germany) with a manual setup |
| — | — | — | — | — | PSMA-11 | 31845408 2020 J Labelled Comp Radiopharm manual setup for routine clinical production |
| — | — | — | — | — | — | 31655351 2020 Appl Radiat Isot |
| — | — | — | — | — | — | 42560334 2026 Radiat Prot Dosimetry |
| — | — | — | — | — | — | 42437859 2026 Discov Oncol |
| — | — | — | — | — | — | 42314598 2026 Bioorg Chem |
| — | — | — | — | — | — | 41986500 2026 Nat Cancer |
| — | — | — | — | — | — | 41698561 2026 Pharmacol Res |
| — | — | — | — | — | — | 33883490 2021 Clin Nucl Med |
| — | — | — | — | — | — | 32149812 2020 Clin Nucl Med |
| — | — | — | — | — | — | 31977467 2020 Clin Nucl Med |
Precursor
- Common precursor
- PSMA-11 (HBED-CC conjugate) PMID 32080309 / DOI 10.1038/s41598-020-60099-y
- Suppliers seen in the literature
- PSMA-11 (Glu-NH-CO-NH-Lys(Ahx)-HBED-CC) precursor from ABX (Radeberg, Germany); also supplied as sterile cold kits (ANMI SA, Liege, Belgium; and the licensed Locametz / Illuccix kits)
- Cited suppliers in indexed syntheses
- ABX, Advanced Biochemical Compounds, Iason GmbH, Novartis, POLATOM, Telix Pharmaceuticals
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [68Ga]Ga-PSMA-11, or handle the enquiry for you.
Get in touchQuality control Pharmacopoeial monograph
- Ph. Eur. monograph
- 3044
- USP monograph
- not verified — the USP-NF monograph index is subscription-only and no public confirmation was found
How this set was arrived at. Base set per Ph. Eur. 0125 + monograph 3044. Ge-68 breakthrough + metal impurities: generator-produced Ga-68 only. RECOMMEND ADD: molar activity / peptide content — PSMA-11 is a saturable-target receptor ligand and monograph 3044 controls peptide content.
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-PSMA-11.
Get in touchNotes
Produced both from generator and from liquid- and solid-target cyclotron Ga-68.